Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI

Hohnloser, Stefan; Steg, Philippe; Oldgren, Jonas; Nickenig, Georg; Kiss, Robert; Ongen, Zeki; Navarro Estrada, Jose; Ophuis, Ton; Lip, Gregory; Nordaby, Matias; Kleine, Eva; ten Berg, Jurrien; Bhatt, Deepak; Cannon, Christopher

doi:10.1016/j.jcin.2019.05.050

Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI

Hohnloser S. H., Steg P. G., Oldgren J., Nickenig G., Kiss R. G., Ongen Z., ...More

JACC-CARDIOVASCULAR INTERVENTIONS, vol.12, no.16, pp.1553-1561, 2019 (SCI-Expanded)

Publication Type: Article / Article
Volume: 12 Issue: 16
Publication Date: 2019
Doi Number: 10.1016/j.jcin.2019.05.050
Journal Name: JACC-CARDIOVASCULAR INTERVENTIONS
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.1553-1561
Istanbul University Affiliated: Yes

Abstract

OBJECTIVES The study sought to evaluate the effect of dabigatran dual therapy versus warfarin triple therapy across categories of renal function in the RE-DUAL PCI (Randomized Evaluation of Dual Antithrombotic Therapy with Dabigatran versus Triple Therapy with Warfarin in Patients with Nonvalvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention) trial.